EUnetHTA has become synonymous with HTA in Europe, a trademark, in fact, that stands for a community of professionals dedicated to continuously improve the standards and quality of their own work, to ultimately achieve ever better results for patients. This dedication of more than 15 years has lead to the creation of a European legal […]
The final report is now available for the Relative Effectiveness Assessment OTCA26 “Surgical procedures for treatment of obesity”. The aim of this multi-technology HTA was to assess the comparative effectiveness (and possible superiority) and safety of different surgical treatments for adult patients with obesity (AGB, SG, RYGB, D-RYGB, OAGB, BPD-DS, BPD,SASI, SADI-S). Only data from […]
We are pleased to publish the EUnetHTA Magazine for Summer 2021, the last issue of Joint Action 3 (2016-2021). While the magazine is intended to publish on a quarterly basis, the changes we have all experienced over the past year and a half have, understandably, presented a challenge to generating articles while our ‘regular’ workflows […]
PTJA16 – Venetoclax in combination with an hypomethylating agent for treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy – final assessment now available
This is the pharmaceutical Joint Assessment PTJA16 – Venetoclax with a hypomethylating agent fort he treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. In June, 2021, the European Commission granted marketing authorisation for Venclyxto® (venetoclax) for the treatment of adult patients with newly diagnosed acute myeloid […]
The European Network for Health Technology Assessment (EUnetHTA) and the European Medicines Agency (EMA) have published a Technical Report on their achievements since 2017. The report covers the latest phase of an open and successful collaboration that began in 2010, and demonstrated that the synergies between regulatory evaluation and health technology assessment (HTA) along […]
We are pleased to publish the minutes for the EUnetHTA-EMA Bilateral meeting held online on 28 April, 2021. This meeting concluded the EMA/EUnetHTA work plan 2017-2021, and attendees celebrated the strengthening of successful collaboration through more than a decade of joint work. Access here: EUnetHTA-EMA Bilateral minutes – 28 April 2021
PTRCR20 – Bamlanivimab for the treatment of COVID-19 Rapid Collaborative Review- Final Rapid Collaborative Review now available.
This is the fourth pharmaceutical Rapid Collaborative Review (PTRCR20) published by EUnetHTA. In March 2021, after an Article 5(3) review the European Medicines Agency (EMA) endorsed the use of bamlanivimab alone and bamlanivimab plus etesevimab combination for the treatment of confirmed COVID-19 in patients aged 12 years and older that do not require supplemental oxygen for […]
PTJA17 – Elivaldogene autotemcel (eli-cel) for treatment of cerebral adrenoleukodystrophy (CALD) – project plan now available
The final project plan of the relative effectiveness assessment of ‘Elivaldogene autotemcel (eli-cel) for treatment of cerebral adrenoleukodystrophy (CALD)’ is now available for access. The final assessment report will be published on 18 August, 2021. Below is the documentation provided by the Joint Assessment Authoring Team. PTJA17 – Final Project Plan
As Joint Action 3 (JA3) comes to a close, an overview of stakeholder interaction has been prepared that focusses on who our stakeholders are, the product-related progress we have made, and all related stakeholder activities through JA3. Access here: Engaging Stakeholders in Joint Action 3
PTRCR19 – REGN-COV2 for the treatment of COVID-19 Rapid Collaborative Review- Final Rapid Collaborative Review now available.
This is the third pharmaceutical Rapid Collaborative Review (PTRCR19) published by EUnetHTA. This report describes REGN-COV2 for the treatment of COVID-19 patients. In March 2021, after an Article 5(3) review the European Medicines Agency (EMA) endorsed the use of REGN-COV2 for the treatment of confirmed COVID-19 in patients aged 12 years and older that do […]